A
Arrakis Therapeutics
Pioneering biopharmaceutical company
About Arrakis Therapeutics
Arrakis Therapeutics is a cutting-edge biotechnology startup that is revolutionizing the field of RNA-targeted small molecule therapeutics, also known as rSM medicines. These are drugs that work by interacting with RNA, a molecule in our cells that plays a crucial role in the production of proteins. By targeting RNA, these drugs can potentially treat a wide range of diseases that are currently difficult to manage.
The company operates in the biotech industry, serving clients such as pharmaceutical companies and research institutions. One of their key partnerships is with Amgen, a multinational biopharmaceutical company, with whom they are working to identify novel RNA degrader small molecule therapeutics. This collaboration is multi-target, meaning it aims to develop drugs that can treat multiple diseases.
Arrakis Therapeutics' business model is based on pioneering new science in the field of rSM medicines. They generate revenue through partnerships with other companies, like Amgen, who are interested in their groundbreaking research and drug development. Additionally, they may also earn income from the sales of any successful drugs that they develop.
The company prides itself on its fearlessness and resilience, and places a strong emphasis on enjoying the journey of scientific discovery. They are always on the lookout for new talent, offering careers in various roles within the company.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Waltham, United States
- Employees
- 53
- Open positions
- None listed
- Dealroom signal
- 27.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2020 | $0 | — | Undisclosed | — |
| SERIES BOther financing | Apr 2019 | $75M | $300M | venBio Partners · Nextech Invest | — |
Growth signals
Latest recorded traffic for Arrakis Therapeutics is 3.3K monthly website visits, down 37.7% over the last three months. Arrakis Therapeutics's team declined 29.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Advent Life Sciences
Series A7 investors entered at this stage
Canaan
Celgene
Henri Termeer
Pfizer
Osage University Partners
venBio Partners
Nextech Invest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arrakis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arrakis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.